| WB | 咨询技术 | Human,Mouse,Rat,Rabbit |
| IF | 咨询技术 | Human,Mouse,Rat,Rabbit |
| IHC | 1/200-1/400 | Human,Mouse,Rat,Rabbit |
| ICC | 技术咨询 | Human,Mouse,Rat,Rabbit |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat,Rabbit |
| Elisa | 咨询技术 | Human,Mouse,Rat,Rabbit |
| Aliases | CDF;HGF;HSF;BSF2;IL-6;BSF-2;IFNB2;IFN-beta-2 |
| Entrez GeneID | 3569 |
| clone | 7C10C6 |
| WB Predicted band size | 23.7kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Rabbit |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于IL6抗体的代表性文献，供参考：
1. **"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis"**
*作者：Emery P. et al.*
**摘要**：该3期临床试验证实，托珠单抗(抗IL6受体单抗)单药治疗可显著降低类风湿关节炎患者的疾病活动度，改善关节症状，且安全性良好。
2. **"Effective treatment of COVID-19 with tocilizumab in patients with severe respiratory failure"**
*作者：Guaraldi G. et al.*
**摘要**：回顾性研究显示，托珠单抗可降低重症COVID-19患者的炎症因子风暴，减少机械通气需求，改善氧合指数及生存率。
3. **"Targeting IL-6 in cancer therapy: Current status and future directions"**
*作者：Kumari N. et al.*
**摘要**：综述探讨了IL-6信号通路在肿瘤微环境中的作用，并总结抗IL6/IL6R抗体在结直肠癌、多发性骨髓瘤等癌症中的治疗潜力及临床挑战。
4. **"Interleukin-6 as a therapeutic target in inflammatory diseases"**
*作者：Rose-John S.*
**摘要**：系统阐述了IL-6在类风湿性关节炎、Castleman病等疾病中的病理机制，并对比了不同IL6靶向抗体(如司妥昔单抗)的作用机理及疗效差异。
注：以上文献信息为示例性质，实际引用时建议通过PubMed等数据库核对原文信息。
Interleukin-6 (IL-6) is a multifunctional cytokine involved in immune regulation, inflammation, hematopoiesis, and tissue repair. It binds to membrane-bound IL-6 receptors (IL-6R) or soluble IL-6R, activating downstream signaling via glycoprotein 130 (gp130), which triggers pathways like JAK/STAT, MAPK, and PI3K. Dysregulated IL-6 signaling is linked to chronic inflammation, autoimmune diseases (e.g., rheumatoid arthritis), and cancers.
IL-6-targeting antibodies were developed to block this pathway. Two main strategies exist: antibodies against IL-6 itself (e.g., siltuximab) or IL-6R (e.g., tocilizumab, sarilumab). Tocilizumab, a humanized anti-IL-6R monoclonal antibody, was first approved in 2010 for rheumatoid arthritis and later for cytokine release syndrome (CRS) in CAR-T therapy and severe COVID-19. Siltuximab, targeting IL-6 directly, is used for multicentric Castleman’s disease. These antibodies reduce inflammation, alleviate symptoms, and improve clinical outcomes.
Research continues to explore their roles in other IL-6-driven conditions, such as certain cancers and inflammatory syndromes. Challenges include managing side effects (e.g., infections, elevated liver enzymes) and optimizing therapeutic efficacy through combination therapies. IL-6 antibodies represent a cornerstone in precision medicine for immune-mediated diseases.
×
